NASDAQ:GTHX - G1 Therapeutics Stock Price, Forecast & News

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

G1 Therapeutics Inc (NASDAQ:GTHX) announced its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.01. View G1 Therapeutics' Earnings History.

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for G1 Therapeutics.

G1 Therapeutics will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 analysts have issued 1 year price objectives for G1 Therapeutics' shares. Their forecasts range from $45.00 to $82.00. On average, they anticipate G1 Therapeutics' stock price to reach $67.17 in the next twelve months. This suggests a possible upside of 280.1% from the stock's current price. View Analyst Price Targets for G1 Therapeutics.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for G1 Therapeutics.

Media stories about GTHX stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. G1 Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for G1 Therapeutics.

G1 Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,080,000 shares, a decline of 13.7% from the December 31st total of 4,730,000 shares. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is presently 12.6 days. Currently, 13.5% of the company's stock are short sold. View G1 Therapeutics' Current Options Chain.

Some companies that are related to G1 Therapeutics include Uniqure (QURE), ChemoCentryx (CCXI), Deciphera Pharmaceuticals (DCPH), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Amicus Therapeutics (FOLD), Arena Pharmaceuticals (ARNA), Biohaven Pharmaceutical (BHVN), ArQule (ARQL), Principia Biopharma (PRNB), Epizyme (EPZM), Aurinia Pharmaceuticals (AUPH), Karuna Therapeutics (KRTX), Ra Pharmaceuticals (RARX) and Synthorx (THOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Rite Aid (RAD), OASMIA PHARMACE/ADR (OASM), Bellicum Pharmaceuticals (BLCM), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Immunomedics (IMMU), Viking Therapeutics (VKTX), Alibaba Group (BABA), Corbus Pharmaceuticals (CRBP) and Eyepoint Pharmaceuticals (EYPT).

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

G1 Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (3.66%), Geode Capital Management LLC (1.11%), Candriam Luxembourg S.C.A. (0.96%), Bank of America Corp DE (0.72%) and Rhenman & Partners Asset Management AB (0.70%). Company insiders that own G1 Therapeutics stock include Barclay A Phillips, Clay Thorp, Cynthia Schwalm, James S Hanson, Jay Strum, Jennifer K Moses, John Demaree, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View Institutional Ownership Trends for G1 Therapeutics.

GTHX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Goldman Sachs Group Inc., UBS Group AG, Signaturefd LLC, Citigroup Inc., Rafferty Asset Management LLC, TD Asset Management Inc. and New York State Common Retirement Fund. View Insider Buying and Selling for G1 Therapeutics.

GTHX stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Candriam Luxembourg S.C.A., Barclays PLC, Tang Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Marshall Wace LLP, Williams Jones Wealth Management LLC. and Alpine Global Management LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Cynthia Schwalm, James S Hanson and John Demaree. View Insider Buying and Selling for G1 Therapeutics.

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GTHX stock can currently be purchased for approximately $17.67.

G1 Therapeutics has a market capitalization of $664.04 million. The company earns $-85,290,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis. G1 Therapeutics employs 84 workers across the globe.View Additional Information About G1 Therapeutics.

The official website for G1 Therapeutics is http://www.g1therapeutics.com/.

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]